US Pharma MarketingGSK to license Hutchmed’s dual-action cancer drug for $110M upfront
GSK to spend $110M upfront licensing Hutchmed Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA…
GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on the line.
The Chinese biopharma said ...
Source: Endpoints News